Infinitopes Granted Phase I/IIa Clinical Trial Application Approval to Evaluate Precision Vaccine Targeting Early-Stage Oesophageal Cancer
- Revolutionary ‘off-the-shelf’ cancer vaccine designed to prevent the recurrence of oesophageal cancer
- ITOP1 to enter first-in-human Phase I/IIa clinical development in the VISTA study in H1 2025
- Multicentre study to be conducted at four university cancer centres, aiming to raise the standard of care by reducing the recurrence of metastases and cancer-related deaths
Oxford, UK – 9 April 2025 – Infinitopes Ltd today announces that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted Clinical Trial Application (CTA) approval for the first-in-human Phase I/IIa clinical trial of ITOP1, the company’s lead ‘off-the-shelf’ cancer vaccine. ITOP1 is a precision cancer vaccine, designed to safely and accurately target tumour antigens, leveraging the company’s vector delivery system, aiming to drive strong and durable T-cell protection for patients with surgically resectable oesophageal adenocarcinoma (OAC).
